1. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001;345:41–52.
2. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. Medicine 2000;79:47–56.
3. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of hepatitis C virus. Arth Rheum1999;42:2204–2212.
4. Pawlotsky J, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995;122:169–173.
5. Pawlotsky J, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective study. Hepatology 1994;19:841–848.
6. Sikuler E, Shnaider A, Zilberman D, et al. Hepatitis C infection and extrahepatic malignancies. J Clin Gastroenterol 1997;24:87–89.
7. Pena L, Nand S, De Maria N, et al. Hepatitis C virus infection and lymphoproliferative disorders. Dig Dis and Sci 2000;45:1854–1860.
8. Meltzer M, Franklin EC. Cryoglobulinemia-a clinical and laboratory study. I. IgG and IgM cyroglobulins and factors affecting cryoprecipitability. Am J Med 1966;40:828.
9. Levey J, Bjornsson B, Banner B, et al. Mixed cryoglobulinemia in chronic hepatitis C infection.Medicine 1994;73:53–67.
10. Ferri C, Greco F, Longombardo G, et al. Antibodies against hepatitis C virus in mixed cryoglobulinemia patients. Infection 1991;19:417–420.
11. Ferri C, La Civita L, Zignego A, et al. Interferon-alpha in mixed cryoglobulinemia patients: randomized, crossover-controlled trial. Blood 1993;81:1132–1136.
12. Agnello V, Chung RT, Kaplan LM, et al. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490–95.
13. Cacoub P, Lunel F, Musset L, et al. Hepatitis C virus and cryoglobulinemia. N Engl J Med1993;328:1121–4.
14. Akriviadis E, Xanthakis I, Navrozidou C, et al. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol 1997;25:612–618.
15. Perniola R, De Rinaldis C, Accogli E, et al. Prevalence and clinical features of cryoglobulinaemia in multitransfused beta-thalassaemia patients. Ann Rheum Dis 1999;58:698–702.
16. Zignego A, Ferri C, Giannini C, et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996;124:31–34.
17. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751–756.
18. Akriviadis E, Xanthakis I, Navrozidou C, et al. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-[alpha]. J Clin Gastroenterol 1997;25:612–618.
19. Killenberg P. Extrahepatic manifestations of chronic hepatitis C. Sem Gastro Dis 2000;11:62–68.
20. Franzin F, Efremov D, Pozzato G. et al. Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br J Haematol 1995;90:548–552.
21. Crouzier R, Martin T, Pasquali J. Monoclonal IgM rheumatoid factor secreted by CD5-negative B cells during mixed cryoglobulinemia. Evidence for somatic mutations and intraclonal diversity of the expressed VH region gene. J Immunol 1995;154:413–21.
22. Sarbah S, Younossi Z. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol2000;30:125–143.
23. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992;339:321–323.
24. Sthoeger Z, Fogel M, Ergas D, et al. Anticardiolipin antibodies in serum samples and cryoglobulins of patients with chronic hepatitis C infection. Ann Rheum Dis 2000;59:483–486.
25. Cacoub P, Ghillani P, Revelen R, et al. Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. J Hepatol 1999;31:598–603.
26. Rajan S, Liebman H. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Amer J Hematol 2001;68:202–209.
27. Pivetti S, Novarino A, Merico F, et al. High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with Lymphoproliferative and connective tissue disorders. Br J Haematol1996;95:204-211.
28. Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003;37:1267–1276.
29. Johnson R, Gretch D, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465–506.
30. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Amer J Med 1999;106:347–352.
31. D’Amico G, Colasanti G, Ferrario F. Renal involvement in essential mixed cryoglobulinemia. Kidney Int 1989;35:1004–1014.
32. Bandi L. Renal manifestations of hepatitis C virus infection. Postgrad Med 2003;113:73–86.
33. Krane K, Gaglio P. Viral hepatitis as a cause of renal disease. South Med J 1999;92:354–360.
34. Marie-Sylvie D. Hepatitis C virus-related skin diseases. Arch Dermatol 1999;135:1401–1403.
35. English JC, Peake MF, Becker LE. Hepatitis C and porphyria cutanea tarda. Cutis 1996;57:404–408.
36. Dupin N, Chosidow O, Lunel F, et al. Essential mixed cryoglobulinemia: a comparative study of dermatologic manifestations in patients infected or noninfected with hepatitis C virus. Arch Dermatol1995;131:1124–1127.
37. Daoud M, Gibson L, Daoud S, et al. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995;70:559–564.
38. Lodi G, Porter SR. Hepatitis C virus infection and lichen planus: a short review. Oral Dis 1997;3:77–81.
39. Schwaber M, Zlotogorski A. Dermatologic manifestations of hepatitis C infection. Int J Dermatol1997;36:251–254.
40. Zaltron S, Puoti M, Liberini P, et al. High prevalence of peripheral neuropathy in hepatitis C infected patients with symptomatic and asymptomatic cryoglobulinemia. Ital J Gastroenterol Hepatol1998;30:391–395.
41. Bonetti B, Scardoni M, Monaco S, et al. Hepatitis C virus infection of peripheral nerves in type II cryoglobulinaemia. Virchows Arch 1999;434:533–535.
42. Heckmann J, Kayser C, Heuss D, et al. Neurological manifestations of chronic hepatitis C. J Neurol1999;246:486–491.
43. Tembl J, Ferrer J, Sevilla M, et al. Neurologic complications associated with hepatitis C virus infection. Neurology 1999;53:861–864.
44. Lacaille F, Zylberberg H, Hagege H, et al. Hepatitis C associated with Guillain-Barre syndrome.Liver 1998;18:49–51.
45. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection fibrosis progression. Gastroenterology 2003;125:1695–1704.
46. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;122:1649–1657.
47. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840–848.
48. Konrad T, Vicini P, Zeuzem S, et al. Interferon-alpha improves glucose intolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Exp Clin Endo Diab 1999;107:343–349.